SR One Summit 2025 Speakers & Panelists
Shreeram Aradhye
As President, Development and Chief Medical Officer for Novartis, Shreeram Aradhye is responsible for advancing the Novartis pipeline of investigational medicines and overseeing medical activities across the company to bring meaningful new treatment options to patients.
Shreeram’s organization leads the development of potential new medicines, running large clinical trials and steering the path to regulatory approval, while generating the evidence needed to ensure our medicines can reach all patients who can benefit. As part of the Novartis strategy, Shreeram and his team play a central role in driving the company’s mid- to long-term growth and delivering on its purpose to improve and extend people’s lives, with a strong pipeline that includes investigational high-value treatments for cardiovascular, renal and immunological conditions, neurological disorders and various forms of cancer.
It’s a true privilege and great responsibility to develop and deliver the next generation of transformational medicines founded in innovative science.
Shreeram is passionate about partnering with patients and physicians to change medical practice, recognizing the hope and trust of clinical trial participants and those who treat and care for them. He has dedicated his professional career to improving patients’ lives, first as an academic clinician and then as a drug developer and business leader.
Shreeram began his current role at Novartis in May 2022, rejoining the company after spending several years at US biotechnology companies, including leading the development of multiple clinical stage RNAi assets at Dicerna Pharmaceuticals. He first joined Novartis in 1999 and over the course of 20 years held a succession of leadership roles in the US, Switzerland, Germany and India, including Global Head of Medical Affairs for the Pharmaceuticals Business Unit and Development Head for the Neuroscience franchise.
Before joining the life sciences industry, Shreeram was an attending physician and assistant professor of medicine and a transplant nephrologist at the University of Pennsylvania. He completed his medical training at the All India Institute of Medical Sciences in 1989, after which he received additional specialty training in internal medicine and nephrology in the US.
Shreeram has a keen interest in photography, leveraging the camera lens as vehicle to notice, be present and observe.
Emmanuelle Charpentier
Awarded the Nobel Prize in 2020, Emmanuelle Charpentier’s ground-breaking work on CRISPR/CAS9 irrevocably changed the genetics landscape. Emmanuelle co-founded ERS Genomics to enable the global life science community to access and benefit from this new technology.
Born in France, Emmanuelle is a microbiologist, geneticist and biochemist. Emmanuelle received her Ph.D from the University Pierre and Marie Curie in Paris, for research performed at the Pasteur Institute. Beyond Paris, Emmanuelle has made scientific contributions in academic institutions across the globe.
Currently at the Max Planck Unit for the Science of Pathogens in Berlin, Emmanuelle has also worked in Paris, New York, Memphis, Vienna, Umeåand Braunschweig.
She has received numerous prestigious national and international awards and distinctions and is an elected member of national and international academies.
Karin Conde-Knape
Karin Conde-Knape is a seasoned executive in the pharmaceutical industry, having formerly served as the Senior Vice President for Early Development at Novo Nordisk. With over 20 years of extensive experience in drug discovery and development, Karin has played a pivotal role in shaping disease area strategies and managing project pipelines, guiding initiatives from target identification through early clinical assessment to ensure that advancements reach the right patients.
A champion for external innovation, Karin has been instrumental in fostering partnerships across Big Pharma, biotechnology companies, venture capital, and academic communities. Her leadership at Novo Nordisk included spearheading early pipelines and driving innovation across diverse therapeutic areas, including diabetes, obesity, cardiovascular, renal, liver, rare endocrine, and rare blood diseases. She has overseen large, global research teams and has successfully navigated various therapeutic modalities.
Throughout her career, Karin has held multiple positions encompassing project leadership, line management, strategic planning, execution, and business development. She is a passionate advocate for diversity, inclusion, and psychological safety in the workplace, consistently creating opportunities for young scientists and mentoring those from underrepresented communities. Her efforts have earned her recognition as a Fierce Leader in the pharmaceutical industry and as one of the top Women in Pharma. Additionally, Karin serves as a board member for several academic institutions, where she actively contributes her industry expertise to enhance educational programs and foster innovation in research.
Prior to her tenure at Novo Nordisk, Karin spent 11 years at Hoffmann-La Roche, where she focused on cardiovascular and metabolism discovery and early development, overseeing pharmacology and biomarker teams. Additionally, she devoted four years to Johnson & Johnson, leading external innovation initiatives in Europe and Asia Pacific in the same therapeutic areas. During this time, she successfully led cross-functional teams in evaluating external opportunities and crafting business cases to support strategic deal-making.
Rajeev Dadoo
Rajeev is COO and Managing Partner of SR One based in the San Francisco Bay Area. He joined SR One in 2004 and is an alum of the Kauffman Fellows Program. Rajeev has leveraged his broad operational and strategic experience to invest in a number of successful companies, both in the therapeutics space and in healthcare-technology companies. His prior roles have included working in the Competitive Excellence group at GSK on various global projects and at Genentech in technology and clinical development. He has also held product development and business development roles at Bio-Rad Laboratories and Genome Therapeutics, respectively, and was a co-founder of Unimicro Technologies.
Rajeev obtained a BA in Chemistry and Mathematics from Knox College, a PhD in Chemistry from Stanford University and an MBA from the Wharton School of the University of Pennsylvania.
Simon Elliot
Senior Managing Director. Investment Banking I Strategic Advisory | London. Simon Elliott is a senior managing director in Evercore's healthcare strategic advisory practice based in London. Having joined Evercore in 2013, he has worked extensively with clients across the healthcare subsectors, including pharma, biotech, medtech and healthcare services for c. 20 years. Recent notable transactions include advising Novartis on the sales of its PET networks to Siemens Healthineers; Novo Nordisk on the acquisition of three manufacturing sites from Catalent; Autolus on the cell therapy collaboration with BioNTech; Novartis on the sale of its “front-of-eye” ophthalmology assets to Bausch + Lomb, Bristol-Myers Squibb on its acquisition of Mirati Therapeutics; Takeda on its acquisition of Nimbus Therapeutics; Novo Nordisk on its acquisition of Dicerna and Emisphere Technologies; AstraZeneca on its acquisition of Alexion; Nestle on the sale of its allergy portfolio, the sale of Galderma (Nestle Skin Health) and on the acquisition of Zenpep; Philips on its acquisitions of BioTelemetry and Capsule Technologies; Sanofi on its acquisition of Principia Biopharma; Eli Lilly on its acquisition of Dermira (and subsequent sale of Qbrexza); Bristol-Myers Squibb on its acquisition of Celgene; AstraZeneca on the sale of its anti-infections business to Pfizer; AstraZeneca on its defense against Pfizer; Shire on its acquisition of Baxalta International; Takeda Pharmaceutical on its acquisition of Shire and subsequent sale of Xiidra to Novartis; Takeda on its acquisition of Ariad Pharmaceuticals; and Partners Group and Duke Street on the acquisition of Voyage Care. Mr. Elliott received a master's in biochemistry from the University of Oxford.
Ronny Gal
In his role as Chief Strategy & Growth Officer, Ronny is responsible for the end-to-end portfolio strategy of Novartis to support the company’s long-term growth, including oversight of corporate strategy, research and development portfolio strategy and business development.
Our company’s next phase of growth will be fueled by the rigor with which we manage our leading pipeline of innovative medicines, guided by the deepest industry insights. I’m honored to lead a function that plays a critical role in unlocking the full potential of the Novartis pipeline for our patients and our business.
Ronny joined Novartis in July 2022, bringing over 20 years of experience in the life-sciences industry spanning financial research and analytics, management consulting, and business development. As a thought leader in the healthcare sector, Ronny is recognized for his deep thematic research across therapeutic areas, technology platforms, and key industry topics such as US healthcare reform.
Prior to joining Novartis, Ronny was the senior analyst covering the US biopharmaceutical industry at Sanford Bernstein, a New York-based research and brokerage firm. Before joining Sanford Bernstein, Ronny started his career with the Boston Consulting Group, where he focused primarily on healthcare.
Ronny holds a doctorate in biochemistry from the Massachusetts Institute of Technology and a bachelor’s degree in chemistry from Emory University, both in the US.
Simeon George
Simeon is CEO and Managing Partner of SR One. Simeon co-founded SR One Capital Management following its spin-out from GSK in 2020. Simeon led SR One’s investments in several marquee deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB), Turning Point Therapeutics (TPTX), Progyny (PGNY), and he co-founded both Nkarta Therapeutics (NKTX) and Arcellx (ACLX).
Simeon has a BA from the Johns Hopkins University and an MD/MBA from the University of Pennsylvania School of Medicine/The Wharton School. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs).
Matthew Harrison
Mr. Harrison joined the Biotechnology investment banking team in May 2023 after 10 years of experience in Morgan Stanley’s Healthcare Equity Research team. He previously led Morgan Stanley’s Biotechnology Research team and covered a variety of biotechnology companies. Prior to joining Morgan Stanley in 2013, Matthew spent 3 years working at UBS as a small / mid cap biotech analyst and an associate on the spec pharma team. Mr. Harrison was a highly ranked biotech analyst in the Institutional Investor All-America poll and was a recognized thought leader at the onset and during the COVID-19 pandemic. He graduated from Yale with a BS in Physics and has an MS in Physics and MSM in Finance from Case Western Reserve University.
Dan Koeppen
Partner, Corporate, San Diego
Dan specializes in corporate governance, mergers and acquisitions, public offerings, and venture capital financings. He has extensive experience representing public and private life science and technology companies in a wide range of sectors, including biotechnology, consumer products, data security, medical device, pharmaceutical, semiconductor, software, and social media, through all stages of their growth from start-up to mature public companies. In addition, Dan represents leading investment banks in their underwriting transactions, and regularly advises numerous venture capital firms and corporate strategic investors in connection with their investments in emerging growth companies.
David M. Lee
As a physician, researcher, and executive leader, David’s career reflects his passion for transforming the lives of patients through innovative science and strategic business approaches. David joined Johnson & Johnson in September 2018, leading an organization focused on discovering, developing and delivering treatments for immune-mediated diseases. Under his leadership, the Immunology portfolio has grown significantly, essentially opening the aperture to treat more diseases and create more, and much needed, options to transform the lives of patients. His organization has launched some of J&J’s most impactful medicines such as STELARA®, TREMFYA®, and IMAAVY.
Before joining Johnson & Johnson, David was based in Basel, Switzerland, where he served as Global Head, Immunology, Inflammation and Infectious Disease Discovery and Translation Area for Roche, and prior to that, as Global Head of Autoimmunity, Dermatology, and Transplant Translational Medicine at the Novartis Institutes for BioMedical Research. In each of these roles, he led on the strategic approaches that fed those companies’ pipelines, prioritized assets, and accelerated their development. His ability to develop external collaborations and to lead and develop his teams was central to his success in each organization.
Before joining industry, David practiced Rheumatology and ran an NIH-funded translational research laboratory at Brigham and Women’s Hospital/Harvard Medical School. While there, he was an active author and speaker, with more than 80 peer reviewed publications and book chapters, and more than 100 lectures/seminars. As a precursor to his career in industry, while at Harvard, he also founded/co-founded three companies, securing venture capital funding. Ultimately, one – a biotech – was acquired by a major pharmaceutical company.
David earned his MD as well as a PhD in Microbiology/Immunology from the Duke University School of Medicine. His passion for developing new medicines is rooted in his experiences treating patients as a practicing rheumatologist.
Zhen Li
Dr. Li is a co-founder of ADARx and a successful executive with more than two decades of diverse experience in research and development in the pharmaceutical and biotech industries. Prior to ADARx, Dr. Li served as Senior VP at Arrowhead Pharmaceuticals where she led the discovery and non-clinical development of Arrowhead’s delivery platform and multiple product candidates that are now in clinical studies. Previously, Dr. Li was a director at Merck, leading a team dedicated to siRNA development. Dr. Li received her Ph.D. in Chemistry and Chemical Biology from Harvard University, and her B.S. from Peking University.
Avaleigh Milne
Avaleigh Milne is the Global Head of Business Development Strategy, for Pharma Partnering at Roche. Partnerships are a core pillar of how Roche innovates for patients and our partnering activities focus on deals that can complement our broad and diverse portfolio across all therapeutic areas and development stages. Avaleigh brings knowledge and experience from a range of business development roles within Roche / Genentech in Basel and San Francisco across multiple therapeutic areas. Prior to Roche, she gained significant industry experience across pharma, venture capital and startups, including at Atlas Venture as a member of their Life Sciences investment team and in Corporate Development at Millennium Pharmaceuticals. She began her career at Bain & Company working with pharma and medtech companies. Avaleigh holds an MBA from Harvard Business School, an MPhil in Bioscience Enterprise from the University of Cambridge, and an AB from Harvard University.
Iqbal Mufti
Iqbal is a Venture Partner at SR One based in our London office focused on company creation, later-stage investments and working with portfolio companies on their engagement with industry and their overall partnering strategy and execution. He is a seasoned pharmaceutical executive with a proven track record in product and portfolio strategy, lifecycle management, late stage development, product launches, global commercialization, affiliate operating leadership, global business development and M&A.
Iqbal recently co-led the rare blood disorders portfolio strategy team at Hoffmann La- Roche where he established the strategy, identified therapeutic focus areas and enabled collaboration across the discovery, development and commercialization teams. Iqbal was also the global Lifecycle Leader for Hemlibra (emicizumab). Under his leadership in the 4 years since launch, Hemlibra was approved in over 100 countries and has become one of the largest absolute and relative growth drivers in the Roche portfolio with over USD 3 billion in revenue in 2021.
Iqbal has significant experience in partnering, having worked on many licensing and acquisitions during his tenure at Roche. He also has operational and commercial experience in multiple territories including the US, Europe and emerging markets. Iqbal holds a BSc in Biotechnology from University College London and a MBA from Fuqua School of Business, Duke University.
Rodger Novak
Dr. Novak is a serial entrepreneur, long-time pharmaceutical and biotechnology senior executive who co-founded CRISPR Therapeutics AG in late 2013. He led the company as CEO until December 2017. During his tenure he IPO’d the company and was responsible for the two landmark deals with Vertex and Bayer. Currently, Dr. Novak serves CRISPR Therapeutics as President and Chair of the Board. He also serves as Executive Chair on the boards of Rockend Ltd, Cambridge, UK, and Matterhorn Biosciences, Basel, Switzerland.
Before CRISPR Therapeutics Dr. Novak was Global Head Infectious Diseases, Sanofi, Paris, France. His responsibility included discovery, research and development, and late stage clinical development of anti-infectives, including diseases of the developing world. In early 2006 Dr. Novak became COO of Nabriva Therapeutics, an antibacterial development company in Vienna, Austria, he co-founded. Nabriva was a spin-out from Sandoz/Novartis, where Dr. Novak served as Vice-Head of the Antibiotic Research Institute.
Dr. Novak received his medical degree in Germany in 1993 and his medical license for the USA in 1994. From 1996 to 2001 he was a postdoctoral fellow at the Rockefeller University, the Skirball Institute, NYU Medical Center, and St Jude Children’s Research Hospital. In 2001, he was appointed as tenured Professor for Microbiology at the Vienna Biocenter, Austria. Dr. Novak authored numerous publications, among them articles in Nature, Nature Medicine and Molecular Cell, provided key contributions in different scientific textbooks in the fields of anti-infectives, genetics and personalized medicine. He is also a co-inventor of several patents.
Michael Palladinetti
Michael Palladinetti is the Global Head of Business Development I&I at Sanofi. Prior to joining in 2017 he held BD roles of increasing responsibility at Bristol-Myers Squibb, Takeda Oncology, Novartis and Auxilium Pharmaceuticals. During his 15+ years in global BD he has successfully executed numerous value creating transactions across the biopharmaceutical value chain.
Michael earned his bachelor’s degree in Biomedical and Electrical Engineering from The Johns Hopkins University, a master’s degree in Bioengineering from University of Pennsylvania and an MBA in Healthcare Management and Strategy from the Wharton School. Michael is a Certified Licensing Professional (CLP).
Christian Rommel
Dr. Rommel is the Executive Vice President, Global Head of Research & Development and Member of the Pharmaceuticals Leadership Team at Bayer, a role he has held since February 2021.
From January 2014 to February 2021, Dr. Rommel served in various roles at Roche, most recently as Senior Vice President, Global Head of Pharma Research and Early Development (pRED) Oncology. Prior to this, Dr. Rommel worked at Amgen where he held roles including Vice President of External Research and Development and Vice President, Research Oncology. Previously, he served as Chief Scientific Officer of Intellikine, a private biotech, from its inception to its acquisition by Takeda Pharmaceuticals.
Dr. Rommel also contributes to the Board of Directors for Asklepios Bio., BlueRock Therapeutics, Vividion Therapeutics, and CRISPR Therapeutics. He also serves on the Board of Trustees for the Max Planck Institute for Molecular Genetics.
Dr. Rommel received his Ph.D. in molecular oncology from the Max Planck Institute in Berlin, Germany and the Institute of Medical Virology at the University of Zurich, Switzerland. In addition to his leadership roles, he lectured biotechnology at the ETH Zurich, Switzerland for several years. He has authored more than 70 publications, including papers in Science and Nature.
Laetitia Schwab
Laetitia is a Senior Associate at SR One based in our London office. Prior to joining SR One in 2022, she worked in clinical development at Orchard Therapeutics where she played a key role in the delivery of a gene therapy (Libmeldy) for Marketing Authorisation. She has experience in early and late-phase clinical programs, designing and executing clinical development strategies with a therapeutic expertise in Gene therapy, Neuroscience and Rare Diseases.
Laetitia received her B.Sc in Medical Sciences from the University of Edinburgh, her MPhil in Translational Medicine and her Ph.D in Clinical Neuroscience from the University of Cambridge and recently completed an MBA at INSEAD.
Chris Sheldon
Chris is currently Senior Vice President & Global Head of Business Development R&D for GSK based in the UK. Chris and his team are responsible for all of GSK's business development activities globally covering the scouting & evaluating, transacting and alliance management of all new investment opportunities.
Chris and his team led the recent $2B acquisition of Bellus Health for phase-III camlipixant in refractory chronic cough and the $1.6B acquisition of Aiolos Bio for IO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway for asthma both adding to GSK’s respiratory medicines portfolio. In addition, two licensing deals were struck with Hansoh Pharma for novel antibody-drug conjugates & a third with WuXi Biologics for bi- & multi-specific T cell engagers in oncology. Finally in the area of infectious disease, a peer licensing deal with Janssen for a phase II-ready siRNA for the treatment of chronic hepatitis.
Prior to this Chris worked in the UK at AstraZeneca (AZ) for over 19 years. Chris held the roles of Vice President & Head of Oncology Business Development in Oncology Research & Development as well as Vice President & Head of Investor Relations.
Chris and his team led the evaluation and investment cases for AZ’s major $6.9B and $6B clinical stage co-development/co-promotion deals with Daiichi-Sankyo for Enhertu (trastuzumab deruxtecan) and DS-1062 (datopotomab deruxtecan), both novel antibody drug conjugates (ADCs). Chris also led AZ’s $6.4B acquisition of Acerta Pharma for Calquence (acalabrutinib), a best-in-class BTK inhibitor in haematology.
Before his business development career, Chris worked in discovery research at AZ as a Senior Research Chemist. He also holds a Ph.D. in Chemistry from the University of Bristol, UK and a first class honours degree from the University of Sheffield, UK.
Amit Shah
Amit is a Principal at SR One based in our London office and covers venture capital investments in biotech. Prior to joining SR One in early 2018, Amit worked in various roles at GlaxoSmithKline including late phase clinical development, global med affairs, and early pipeline commercial strategy. He is a board certified equivalent plastic surgeon, specialised in microsurgical cancer reconstruction. Since 2020, Amit has sat on the venture capital panel for the BioInnovation Institute, Novo Nordisk’s international life sciences incubator.
Amit received his B.A. in Medical Sciences, M.A. in Neuroscience and M.D from the University of Cambridge, UK
Nenad Tomasevic
Nenad Tomasevic co-founded Dren Bio as CEO in May 2019 and has served on our board of directors since inception. Dr. Tomasevic most recently served as Vice President of Research for Allakos, a company he helped co-found after identifying the original opportunity for developing therapeutic antibodies against Siglec-8. During his time at Allakos, he was responsible for all research and nonclinical development functions. Prior to co-founding Allakos, Dr. Tomasevic previously held positions at KaloBios and Nuvelo, where his focus was on the development of therapeutic antibodies. Dr. Tomasevic began his career at Cytokinetics after receiving his PhD in protein chemistry from the University of Belgrade and completing his postdoctoral training at the National Institutes of Health (NIDDK, Genetics and Biochemistry Branch) in Bethesda, Maryland.